Criminal or bystander: imatinib and second primary malignancy in GIST patients

被引：8
|
作者：
Kanda, Tatsuo [1 ]
机构：
[1] Sanjo Gen Hosp, Sanjo City, Niigata 9550055, Japan
来源：
CHINESE JOURNAL OF CANCER RESEARCH | 2013年 / 25卷 / 05期
关键词：
GASTROINTESTINAL STROMAL TUMORS; NEOPLASMS; COEXISTENCE; KIT;
D O I：
10.3978/j.issn.1000-9604.2013.10.15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490 / 492
页数：3
相关论文
共 50 条
  • [1] Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis
    Petrelli, Fausto
    Tomasello, Gianluca
    Barni, Sandro
    Varrichio, Antonio
    Costanzo, Antonio
    Rampulla, Valentina
    Cabiddu, Mary
    Turati, Luca
    Russo, Alessandro
    Seghezzi, Silvia
    Passalacqua, Rodolfo
    Ghidini, Michele
    SURGICAL ONCOLOGY-OXFORD, 2019, 29 : 64 - 70
  • [2] Sunitinib Treatment in Pediatric Patients With Advanced GIST Following Failure of Imatinib
    Janeway, Katherine A.
    Albritton, Karen H.
    Van Den Abbeele, Annick D.
    D'Amato, Gina Z.
    Pedrazzoli, Paolo
    Siena, Salvatore
    Picus, Joel
    Butrynski, James E.
    Schlemmer, Marcus
    Heinrich, Michael C.
    Demetri, George D.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (07) : 767 - 771
  • [3] Analysis and prediction of second primary malignancy in patients with breast cancer
    Long, Quanyi
    Zhao, Feilong
    Li, Hongjiang
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (06)
  • [4] Long-term outcome of GIST patients treated with delayed imatinib therapy
    Kurtovic-Kozaric, Amina
    Kugic, Amina
    Hasic, Azra
    Beslija, Semir
    Ceric, Timur
    Pasic, Anes
    Vranic, Semir
    Kopric, Dijana
    Iljazovic, Ermina
    Barbuscia, Jelena Todorovic
    Kozaric, Mirza
    Ibisevic, Nermina
    Keskic, Leila
    Kurtovic, Sabira
    EUROPEAN JOURNAL OF CANCER, 2017, 78 : 118 - 121
  • [5] Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients
    Valadao, Marcus
    Braggio, Danielle
    Santos, Anna Flavia
    Pimenta-Inada, Haynna Kimie
    Linhares, Eduardo
    Goncalves, Rinaldo
    Romano, Sergio
    Vilhena, Bruno
    Small, Isabele
    Cubero, Daniel
    Cruz, Felipe
    Oliveira, Antonio Talvane
    Martinho, Olga
    Reis, Rui Manuel
    Guimaraes, Denise Peixoto
    Ferreira, Carlos Gil
    JOURNAL OF SURGICAL RESEARCH, 2012, 178 (01) : 288 - 293
  • [6] Imatinib plasma levels: correlation with clinical benefit in GIST patients
    Widmer, N.
    Decosterd, L. A.
    Csajka, C.
    Montemurro, M.
    Haouala, A.
    Leyvraz, S.
    Buclin, T.
    BRITISH JOURNAL OF CANCER, 2010, 102 (07) : 1198 - 1199
  • [7] Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma
    Zhang, Guoqing
    Wu, Bin
    Wang, Xiaofei
    Li, Jindong
    MEDICINE, 2019, 98 (36)
  • [8] Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
    Schiavon, Gaia
    Ruggiero, Alessandro
    Schoeffski, Patrick
    van der Holt, Bronno
    Bekers, Dave J.
    Eechoute, Karel
    Vandecaveye, Vincent
    Krestin, Gabriel P.
    Verweij, Jaap
    Sleijfer, Stefan
    Mathijssen, Ron H. J.
    PLOS ONE, 2012, 7 (11):
  • [9] Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
    Hompland, Ivar
    Bruland, Oyvind S.
    ANTICANCER RESEARCH, 2015, 35 (11) : 5759 - 5765
  • [10] Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
    Fiore, M.
    Palassini, E.
    Fumagalli, E.
    Pilotti, S.
    Tamborini, E.
    Stacchiotti, S.
    Pennacchioli, E.
    Casali, P. G.
    Gronchi, A.
    EJSO, 2009, 35 (07): : 739 - 745
12345